最新ニュース Exelixis (NASDAQ:EXEL) 株価情報

Exelixis

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis Inc

EXELA TECHNOLOGIES INC by Exela Technologies, Inc.

Exela Technologies Inc

EXELA TECHS INC 6% SER B by Exela Technologies, Inc.

Exelon Corp

UBS analyst Ashwani Verma maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Neutral and raises the price target from $30 to $34.

News

Price Target

Analyst Ratings

EXEL

UBS Maintains Neutral on Exelixis, Raises Price Target to $34

JMP Securities analyst Silvan Tuerkcan maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Market Outperform and maintains $41 price target.

JMP Securities Maintains Market Outperform on Exelixis, Maintains $41 Price Target

Truist Securities analyst Asthika Goonewardene maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and raises the price target from $42 to $43.

Truist Securities Maintains Buy on Exelixis, Raises Price Target to $43

Stephens &amp; Co. analyst Sudan Loganathan reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Equal-Weight and maintains $29 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Exelixis, Maintains $29 Price Target

HC Wainwright &amp; Co. analyst Robert Burns reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and maintains $40 price target.

HC Wainwright & Co. Reiterates Buy on Exelixis, Maintains $40 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley slashed the price target for Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) from $56 to $11. Morgan Stanley analyst Terence Flynn downgraded the stock from Overweight to Equal-Weight. Intellia Therapeutics shares closed at $10.99 on Friday. <a href="https://www.benzinga.com/quote/NTLA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut McCormick &amp; Company, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>) price target from $85 to $82. Barclays analyst Andrew Lazar maintained an Equal-Weight rating. McCormick shares closed at $74.89 on Friday. <a href="https://www.benzinga.com/quote/MKC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays raised the price target for Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) from $149 to $158. Barclays analyst Matt Miksic maintained an Overweight rating. Abbott shares closed at $125.03 on Friday. <a href="https://www.benzinga.com/quote/ABT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs raised the price target for Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) from $77 to $185. Goldman Sachs analyst Kash Rangan upgraded the stock from Neutral to Buy. Twilio shares closed at $136.23 on Friday. <a href="https://www.benzinga.com/quote/TWLO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies cut RLI Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLI#NYSE">RLI</a>) price target from $95 to $61. Jefferies analyst Andrew Andersen downgraded the stock from Buy to Underperform. RLI shares settled at $72.48 on Friday. <a href="https://www.benzinga.com/quote/RLI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley raised Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) price target from $30 to $40. Morgan Stanley analyst Jefferson Harralson upgraded the stock from Equal-Weight to Overweight. Exelixis shares closed at $32.38 on Friday. <a href="https://www.benzinga.com/quote/EXEL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan decreased Omnicom Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>) price target from $119 to $116. JP Morgan analyst David Karnovsky maintained an Overweight rating. Omnicom shares closed at $86.56 on Friday.  <a href="https://www.benzinga.com/quote/OMC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel raised the price target for Portillo&#8217;s Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLO#NASDAQ">PTLO</a>) from $13 to $16. Stifel analyst Chris O&#8217;Cull upgraded the stock from Hold to Buy. Portillo&#8217;s shares settled at $12.49 on Friday. <a href="https://www.benzinga.com/quote/PTLO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut RingCentral, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) price target from $45 to $37. Barclays analyst Ryan Macwilliams downgraded the stock from Overweight to Equal-Weight. RingCentral shares closed at $34.65 on Friday. <a href="https://www.benzinga.com/quote/RNG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler increased Qorvo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) price target from $85 to $110. Piper Sandler analyst Harsh Kumar upgraded the stock from Neutral to Overweight. Qorvo shares closed at $88.94 on Friday. <a href="https://www.benzinga.com/quote/QRVO/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/markets/25/01/43189390/top-3-materials-stocks-that-may-fall-off-a-cliff-in-january">Top 3 Materials Stocks That May Fall Off A Cliff In January</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

NTLA

PTLO

QRVO

TWLO

Abbott To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst Kash Rangan upgraded the rating for Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) from Neutral to Buy and raised the price target from $77 to $185. Twilio shares closed at $136.23 on Friday. <a href="https://www.benzinga.com/quote/TWLO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Jefferson Harralson upgraded Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) from Equal-Weight to Overweight and raised the price target from $30 to $40. Exelixis shares closed at $32.38 on Friday. <a href="https://www.benzinga.com/quote/EXEL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst David Karnovsky upgraded the rating for The Interpublic Group of Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>) from Neutral to Overweight and boosted the price target from $32 to $39. Interpublic shares closed at $28.54 on Friday. <a href="https://www.benzinga.com/quote/IPG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Christopher Schoell upgraded Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) from Neutral to Buy and increased the price target from $175 to $230. Take-Two Interactive shares closed at $185.49 on Friday. <a href="https://www.benzinga.com/quote/TTWO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst David Leiker upgraded Aptiv PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) from Neutral to Outperform and raised the price target from $75 to $82. Aptiv shares closed at $63.43 on Friday. <a href="https://www.benzinga.com/quote/APTV/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TWLO stock? Here&#8217;s what analysts think: 

<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="600" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/27064341/image-204-1024x600.png" alt="" class="wp-image-750977" style="width:549px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/27064341/image-204-1024x600.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/27064341/image-204-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/27064341/image-204-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/27064341/image-204.png 1087w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43189390/top-3-materials-stocks-that-may-fall-off-a-cliff-in-january">Top 3 Materials Stocks That May Fall Off A Cliff In January</a></li>
</ul>

Upgrades

APTV

TTWO

This Twilio Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Morgan Stanley analyst Jefferson Harralson upgrades Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) from Equal-Weight to Overweight and raises the price target from $30 to $40.

Morgan Stanley Upgrades Exelixis to Overweight, Raises Price Target to $40

– In a subgroup analysis of patients without liver metastases, adding atezolizumab to zanzalintinib led to enhanced progression-free survival and overall survival –

Reported Saturday, Exelixis Unveils Outcomes From Phase 1b/2 STELLAR-001 Trial Of Zanzalintinib As Monotherapy Or Combined With An Immune Checkpoint Inhibitor In Metastatic Colorectal Cancer At ASCO GI 2025

Biotech

General

Exelixis To Present Results From Subgroup Analysis Of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib In Advanced Gastrointestinal Neuroendocrine Tumors Presented At ASCO GI 2025  At 11:30 a.m. PT on January 24; Cabozantinib Reduced The Risk Of Disease Progression Or Death By 50% Compared With Placebo In Patients With Advanced Gastrointestinal Neuroendocrine Tumors

WIIM

Exelixis shares are trading lower after Oppenheimer downgraded the stock from Outperform to Perform and cut its price target from $41 to $33.

Oppenheimer analyst Jay Olson downgrades Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) from Outperform to Perform and lowers the price target from $41 to $33.

Downgrades

Oppenheimer Downgrades Exelixis to Perform, Lowers Price Target to $33

JMP Securities analyst Silvan Tuerkcan reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Market Outperform and maintains $41 price target.

JMP Securities Reiterates Market Outperform on Exelixis, Maintains $41 Price Target

Guggenheim analyst Michael Schmidt reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) from Buy to Buy.

Guggenheim Reiterates Buy on Exelixisto Buy

Oppenheimer analyst Jay Olson maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Outperform and raises the price target from $38 to $41.

Oppenheimer Maintains Outperform on Exelixis, Raises Price Target to $41

15 analysts have shared their evaluations of Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Exelixis, presenting an average target of $37.13, a high estimate of $42.00, and a low estimate of $29.00. This current average reflects an increase of 15.06% from the previous average price target of $32.27. 
<img src="https://www.benzinga.com/files/images/story/2025/1736971236_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Exelixis's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$40.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$36.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$36.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Exelixis's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exelixis analyst ratings.</a>
<h2>Discovering Exelixis: A Closer Look</h2>
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Understanding the Numbers: Exelixis's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Exelixis's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.33% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Exelixis's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 21.87%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Exelixis's ROE stands out, surpassing industry averages. With an impressive ROE of 5.37%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Exelixis's ROA excels beyond industry benchmarks, reaching 4.12%. This signifies efficient management of assets and strong financial health.
Debt Management: Exelixis's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

15 Analysts Have This To Say About Exelixis

Truist Securities analyst Asthika Goonewardene maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and raises the price target from $38 to $42.

Truist Securities Maintains Buy on Exelixis, Raises Price Target to $42

JMP Securities analyst Silvan Tuerkcan maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Market Outperform and raises the price target from $34 to $41.

JMP Securities Maintains Market Outperform on Exelixis, Raises Price Target to $41

Piper Sandler analyst Joseph Catanzaro maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Overweight and raises the price target from $36 to $37.

Piper Sandler Maintains Overweight on Exelixis, Raises Price Target to $37

<ul>
<li>– Cabozantinib franchise achieves approximately $1.805 billion in preliminary U.S. net product revenues for fiscal year 2024 –</li>
<li>– Fiscal year 2025 net product revenues guidance of $1.95 billion - $2.05 billion –</li>
<li>– Presentation and webcast at 43rd Annual J.P. Morgan Healthcare Conference tomorrow, Monday, January 13th at 5:15 p.m. PT / 8:15 p.m. ET –</li>
</ul>

Reported Earlier, Exelixis Reports $2.165B In Preliminary 2024 Revenue, Projects $2.15B-2.25B In 2025, And Highlights Pipeline Progress

Analyst David Lebowitz from Citi maintained a Buy rating on Exelixis (EXEL – Research Report) and keeping the price target at $38.00. David Lebowit...

Exelixis's Cabozantinib Shows Promising Results for NET: Analyst Recommends 'Buy'

Exelixis (EXEL) announced results from an expansion cohort of the phase 1b/2 STELLAR-001 trial evaluating zanzalintinib alone or in combination wit...

Exelixis announces results from expansion cohort of phase 1b/2 STELLAR-001

In a report released yesterday, Sean Laaman from Morgan Stanley upgraded Exelixis (EXEL – Research Report) to a Buy, with a price target of $40.00....

Optimistic Outlook for Exelixis Driven by Growth Potential in Cabometyx and Zanzalintinib

Morgan Stanley upgraded Exelixis (EXEL) to Overweight from Equal Weight with a price target of $40, up from $30, after assuming coverage of the nam...

Exelixis upgraded to Overweight from Equal Weight at Morgan Stanley

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of $41.00. Silvan ...

Exelixis's Strategic Advancements in mCRC Market Capture Analyst's Buy Rating

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Exelixis (EXEL – Research Report). The associated price target remains ...

Promising Clinical Data Supports Buy Rating for Exelixis with Target Price of $40

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Scilex Holding Company (SCLX – Research Report) and ...

Analysts Are Bullish on Top Healthcare Stocks: Scilex Holding Company (SCLX), Exelixis (EXEL)

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Exelixis (EXEL – Research Report), with a price target of $34.00....

Exelixis (EXEL) Gets a Buy from TD Cowen

Stifel Nicolaus analyst Stephen Willey maintained a Hold rating on Exelixis (EXEL – Research Report) today and set a price target of $30.00. The co...

Stifel Nicolaus Sticks to Their Hold Rating for Exelixis (EXEL)

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong stock performance. With a dedicated focus on cancer treatment innovation and an expanding market footprint, could EXEL be the next biotech stock to add to your portfolio? Read on to find out… In the fast-growing biotechnology sector, driven by advances in gene editing, personalized medicine, and artificial intelligence, companies are racing to develop new treatments for an aging population and the increasing demand for healthcare. Among the innovators in this space, Exelixis, Inc. (<a href="https://stocknews.com/stock/EXEL/">EXEL</a>) is gaining significant attention, and for good reason.
Exelixis is zeroing in on difficult-to-treat cancers armed with a clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs), and other biotherapeutics. The company leverages cutting-edge science, strategic collaborations, and significant investments to broaden its reach across various tumor types.
EXEL delivered exceptional results in its fiscal <a href="https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-third-quarter-2024-financial-results-and">third quarter</a>, surpassing analyst expectations while demonstrating the strength of its cancer-focused portfolio. The company's flagship product, CABOMETYX&#xAE;, continues to make waves alongside promising treatments like Zanzalintinib, XB010, and XL495. With many of these therapies still in trial phases or awaiting FDA approvals, EXEL is relentlessly working to improve treatment options.
In terms of price performance, the stock has returned 17.4% in the past three months, while over the past year, it rose by an impressive 47.9%, closing the last trading session at $32.73.
As we look ahead, 2025 could be a defining year for Exelixis. With a robust pipeline and an ongoing push for innovation, this company is on track for more clinical and regulatory milestones. But is EXEL a biotech stock worth adding to your portfolio?
Let's explore the factors that could shape the company's performance in the near future.
A Robust Pipeline Beyond Cabometyx
Exelixis isn't resting on its laurels with the success of CABOMETYX&#xAE;. The company is aggressively expanding its oncology portfolio with promising candidates like zanzalintinib, a next-generation oral tyrosine kinase inhibitor (TKI). This drug is being tested in the STELLAR-303 study, where it's combined with Tecentriq to treat advanced colorectal cancer. With enrollment now complete, early results from this pivotal trial are anticipated in 2025, potentially opening new doors for treatment options in a challenging cancer type.
Adding to its momentum, EXEL recently <a href="https://ir.exelixis.com/news-releases/news-release-details/exelixis-and-merck-sign-clinical-development-collaboration">partnered</a> with pharmaceutical heavyweight Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>) to explore zanzalintinib's potential combined with MRK's blockbuster PD-1 therapy Keytruda (pembrolizumab). This collaboration spans several studies, including a late-stage trial for head and neck squamous cell carcinoma (HNSCC) and a phase I/II trial using Merck's hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, Welireg, for renal cell carcinoma (RCC).
By diversifying its pipeline, EXEL is reducing its reliance on CABOMETYX&#xAE; and aiming for long-term growth. These efforts could pave the way for a new wave of therapies that improve outcomes for cancer patients worldwide.
Robust Financials and Upbeat Guidance
During the third quarter that ended September 30, 2024, EXEL's total revenue increased 14.3% year-over-year to $539.54 million. Its income from operations income came in at $136.07 million compared to a year-ago loss of $17.58 million.
In addition, the company's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> amounted to $135.66 million or $0.47 per share, reflecting a considerable improvement from $32.09 million or $0.10 per share, respectively, recorded in the same period last year.
Recently, the company announced its preliminary unaudited financial results for the fiscal year 2024, provided financial guidance for the fiscal year 2025, and delivered an update on its business. Total revenues are projected to be between $2.15 billion and $2.25 billion (previous guidance: $1.975-$2.075 billion). Net product revenues are estimated to be in the band of $1.95-$1.2.05 billion (previous guidance: $1.65-$1.75 billion).
Solid Historical Growth
EXEL's revenue and EBITDA have grown at respective CAGRs of 18.4% and 45% over the past three years. The company's EBIT has increased 46.3% over the same timeframe, while its net income and EPS have improved at CAGRs of 41.7% and 44.8%, respectively.
Also, the company's total assets and levered free cash flow have grown at CAGRs of 6.5% and 25.6% over the past three years, respectively.
Favorable Analyst Estimates
Analysts expect EXEL's EPS for the fourth quarter (ended December 2024) to increase 56.7% year-over-year to $0.42. Its revenue for the same quarter is expected to come in at $558.60 million, reflecting a growth of 16.5% from the prior year. Furthermore, the company has surpassed the consensus EPS and revenue estimates in three of the trailing four quarters, which is promising.
Additionally, Street expects the company's revenue and EPS for the fiscal year (ending December 2025) to increase 3.6% and 8.6% year-over-year to $2.23 billion and $1.89, respectively.
High Profitability
EXEL's trailing-12-month gross profit margin of 96.25% is 65.9% higher than the respective industry average of 58%. Its trailing-12-month EBIT margin of 29.22% is significantly higher than the industry average of 2.39%.
Furthermore, the stock's trailing-12-month net income, ROCE, and ROTA of 22.43%, 20.20%, and 15.77% favorably compare to the negative industry averages of 4.61%, 40.27%, and 26.01%, respectively. Similarly, its trailing-12-month levered FCF margin of 20.72% is considerably higher than the industry average of 2.50%.
POWR Ratings Reflect Promise
EXEL's robust prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, translating to a Strong Buy in our proprietary system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. EXEL has an A grade for Value and Quality, which is in sync with its lower-than-industry valuations and robust profitability, respectively.
Also, the stock has a B grade for Growth, consistent with its strong financial performance and historical growth.
Among the 333 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, EXEL is ranked #3. Beyond what I have stated above, we have also given EXEL grades for Momentum, Sentiment, and Stability. Get access to all the EXEL ratings <a href="https://stocknews.com/stock/EXEL/">here</a>.
Bottom Line
EXEL reported better-than-expected financial results for the third quarter. Analysts appear bullish about the company's growth prospects, driven by robust demand for its quality and diverse product offerings, expanding pipeline, strategic collaborations, and strong market position. Also, its growing revenue and gross profit margin depict solid financial health.
Given EXEL's solid financials, accelerating profitability, and promising growth outlook, this stock could be an ideal buy now.
How Does Exelixis, Inc. (EXEL) Stack Up Against Its Peers?
While EXEL has an overall POWR Rating of A, investors could also check out these other stocks within the Biotech industry with A (Strong Buy) or B (Buy) ratings: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>), Jazz Pharmaceuticals plc (<a href="https://stocknews.com/stock/JAZZ/">JAZZ</a>), and Otsuka Holdings Co., Ltd. (<a href="https://stocknews.com/stock/OTSKY/">OTSKY</a>).
For exploring more A and B-rated biotech stocks, <a href="https://stocknews.com/category/biotech/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
EXEL shares were trading at $32.83 per share on Tuesday afternoon, up $0.10 (+0.31%). Year-to-date, EXEL has declined -1.41%, versus a 3.01% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/exel-gild-jazz-otsky-mrk-is-exelixis-a-biotech-stock-worth-adding-to-your-portfolio/>Is Exelixis a Biotech Stock Worth Adding to Your Portfolio?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Exelixis a Biotech Stock Worth Adding to Your Portfolio?

GILD

JAZZ

OTSKY

SCLX

Press Releases

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

Sairopa reports research milestones achieved in partnership with Exelixis, totalling $35 Million from consecutive clinical milestone payments in 2024

Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025

Comments

Exelixis

ニュース

最新ニュース Exelixis (NASDAQ:EXEL) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル